Patriot Financial Group Insurance Agency LLC Sells 1,879 Shares of Novo Nordisk A/S (NYSE:NVO)

Patriot Financial Group Insurance Agency LLC trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 15.1% during the 4th quarter, HoldingsChannel reports. The firm owned 10,589 shares of the company’s stock after selling 1,879 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in Novo Nordisk A/S were worth $911,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Xponance Inc. increased its position in Novo Nordisk A/S by 27.6% in the second quarter. Xponance Inc. now owns 2,665 shares of the company’s stock worth $380,000 after purchasing an additional 576 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 110.5% in the 2nd quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock worth $2,450,000 after buying an additional 9,012 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Novo Nordisk A/S by 2.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 131,876 shares of the company’s stock valued at $18,824,000 after buying an additional 2,817 shares in the last quarter. Sunbelt Securities Inc. lifted its holdings in shares of Novo Nordisk A/S by 1.3% in the 2nd quarter. Sunbelt Securities Inc. now owns 10,752 shares of the company’s stock valued at $1,535,000 after acquiring an additional 138 shares during the last quarter. Finally, EP Wealth Advisors LLC grew its position in Novo Nordisk A/S by 37.6% in the second quarter. EP Wealth Advisors LLC now owns 65,844 shares of the company’s stock worth $9,399,000 after acquiring an additional 17,982 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on NVO shares. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Down 2.9 %

NYSE:NVO opened at $85.00 on Wednesday. The stock has a fifty day simple moving average of $95.10 and a 200-day simple moving average of $114.43. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a market cap of $381.45 billion, a price-to-earnings ratio of 27.51, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.